We aspire to bring drugs and medical devices to patients, caregivers and health care providers.

Nobelpharma strives to efficiently develop drugs and medical devices for conditions with limited or no other treatment options or that may go overlooked because of the small number of patients affected. We work to contribute to medical care by developing, manufacturing and delivering essential medicines that other companies might not pursue. Our efficient R&D process allows us to effectively bring products to the market as quickly as possible to provide patients and physicians with treatments that are greatly needed.

Shigeki Shimasaki

Mr. Shigeki Shimasaki,
Vice President & COO (Head of Research & Development) of
Nobelpharma Co. Ltd.

Facial angiofibroma associated with tuberous sclerosis complex (TSC)

Sirolimus topical gel 0.2% (NPC-12G)* is a topical mTOR inhibitor, currently under review with the U.S. Food and Drug Administration (FDA) with a target indication for treatment of facial angiofibroma associated with TSC.

The U.S. FDA has not yet made a determination as to the safety and effectiveness of this product for the target indication.

Nobelpharma received approval in Japan (2018)*

Adductor spasmodic dysphonia

(NPC-17)* is a medical device approved in Japan for type II thyroplasty for the treatment of adductor spasmodic dysphonia.


Nobelpharma received approval in Japan (2018)*

Tympanic membrane perforation (TMP)

(NPC-18)* is a drug approved in Japan for the treatment of tympanic membrane perforation.



Nobelpharma received approval in Japan (2019)*

*Nobelpharma products are approved in Japan only and the drugs have not been approved or deemed safe and effective by the U.S. FDA and are not available for commercial sale in the U.S. NPC-18 and NPC-17 are investigational only in the U.S.

This website contains information about products that may not be available in the U.S. Nothing contained herein should be considered a solicitation, promotion or advertisement for any product including those under development.